Abstract
Cardiac amyloidosis, the majority of cases of which are due to immunoglobulin light chain amyloidosis (AL) and transthyretin amyloidosis (ATTR), affects different aspects of the heart and cardiovascular system. Amyloid-induced cardiomyopathy, clinically manifesting with heart failure and electrophysiological abnormalities, has distinct characteristics compared to non-amyloid cardiomyopathies. Accordingly, specific management strategies are required. This paper will review the cardiovascular manifestations of patients with cardiac amyloidosis and their suggested treatment strategies, emphasizing the importance of multidisciplinary care.
References
1.
Shi
J
, Guan
J
, Jiang
B
, Brenner
DA
, Del Monte
F
, Ward
JE
, et al. Amyloidogenic light chains induce cardiomyocyte contractile dysfunction and apoptosis via a non-canonical p38alpha MAPK pathway
. Proc Natl Acad Sci USA
. 2010
Mar
;107
(9
):4188
–93
.
[PubMed]
0027-84242.
Brenner
DA
, Jain
M
, Pimentel
DR
, Wang
B
, Connors
LH
, Skinner
M
, et al. Human amyloidogenic light chains directly impair cardiomyocyte function through an increase in cellular oxidant stress
. Circ Res
. 2004
Apr
;94
(8
):1008
–10
.
[PubMed]
0009-73303.
Ponikowski
P
, Voors
AA
, Anker
SD
, Bueno
H
, Cleland
JG
, Coats
AJ
, et al.; Authors/Task Force Members
; Document Reviewers
. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC
. Eur J Heart Fail
. 2016
Aug
;18
(8
):891
–975
.
[PubMed]
1388-98424.
Mesquita
ET
, Jorge
AJ
, Souza
CV
, Andrade
TR
. Cardiac Amyloidosis and its New Clinical Phenotype: Heart Failure with Preserved Ejection Fraction
. Arq Bras Cardiol
. 2017
Jul
;109
(1
):71
–80
.
[PubMed]
0066-782X5.
Sperry
BW
, Jones
BM
, Vranian
MN
, Hanna
M
, Jaber
WA
. Recognizing Transthyretin Cardiac Amyloidosis in Patients With Aortic Stenosis: impact on Prognosis
. JACC Cardiovasc Imaging
. 2016
Jul
;9
(7
):904
–6
.
[PubMed]
1936-878X6.
Vermeer
AM
, Janssen
A
, Boorsma
PC
, Mannens
MM
, Wilde
AA
, Christiaans
I
. Transthyretin amyloidosis: a phenocopy of hypertrophic cardiomyopathy
. Amyloid
. 2017
Jun
;24
(2
):87
–91
.
[PubMed]
1350-61297.
Falk
RH
, Alexander
KM
, Liao
R
, Dorbala
S
. AL (Light-Chain) Cardiac Amyloidosis: A Review of Diagnosis and Therapy
. J Am Coll Cardiol
. 2016
Sep
;68
(12
):1323
–41
.
[PubMed]
0735-10978.
Dorbala
S
, Cuddy
S
, Falk
RH
. How to Image Cardiac Amyloidosis: A Practical Approach
. JACC Cardiovasc Imaging
. 2019
Oct
;S1936-878X(19)30713-2
.
[PubMed]
1876-75919.
Abdalla
I
, Murray
RD
, Lee
JC
, Stewart
WJ
, Tajik
AJ
, Klein
AL
. Duration of pulmonary venous atrial reversal flow velocity and mitral inflow a wave: new measure of severity of cardiac amyloidosis
. J Am Soc Echocardiogr
. 1998
Dec
;11
(12
):1125
–33
.
[PubMed]
0894-731710.
Castaño
A
, Narotsky
DL
, Hamid
N
, Khalique
OK
, Morgenstern
R
, DeLuca
A
, et al. Unveiling transthyretin cardiac amyloidosis and its predictors among elderly patients with severe aortic stenosis undergoing transcatheter aortic valve replacement
. Eur Heart J
. 2017
Oct
;38
(38
):2879
–87
.
[PubMed]
0195-668X11.
Witteles
RM
, Liedtke
M
. AL Amyloidosis for the Cardiologist and Oncologist
. Epidemiology, Diagnosis, and Management
. 2019
;1
(1
):117
–30
. 12.
Palladini
G
, Merlini
G
. What is new in diagnosis and management of light chain amyloidosis?
Blood
. 2016
Jul
;128
(2
):159
–68
.
[PubMed]
0006-497113.
Wechalekar
AD
, Gillmore
JD
, Bird
J
, Cavenagh
J
, Hawkins
S
, Kazmi
M
, et al.; BCSH Committee
. Guidelines on the management of AL amyloidosis
. Br J Haematol
. 2015
Jan
;168
(2
):186
–206
.
[PubMed]
0007-104814.
Pfeffer
MA
, Claggett
B
, Assmann
SF
, Boineau
R
, Anand
IS
, Clausell
N
, et al. Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) trial
. Circulation
. 2015
Jan
;131
(1
):34
–42
.
[PubMed]
0009-732215.
Merlini
G
, Dispenzieri
A
, Sanchorawala
V
, Schönland
SO
, Palladini
G
, Hawkins
PN
, et al. Systemic immunoglobulin light chain amyloidosis
. Nat Rev Dis Primers
. 2018
Oct
;4
(1
):38
.
[PubMed]
2056-676X16.
John
R
. Arrythmias in cardiac amyloidosis
. J Innov Card Rhythm Manag
. 2018
;9
:3051
–7
. 17.
Muchtar
E
, Buadi
FK
, Dispenzieri
A
, Gertz
MA
. Immunoglobulin Light-Chain Amyloidosis: From Basics to New Developments in Diagnosis, Prognosis and Therapy
. Acta Haematol
. 2016
;135
(3
):172
–90
.
[PubMed]
0001-579218.
Gertz
MA
, Skinner
M
, Connors
LH
, Falk
RH
, Cohen
AS
, Kyle
RA
. Selective binding of nifedipine to amyloid fibrils
. Am J Cardiol
. 1985
Jun
;55
(13 Pt 1
):1646
.
[PubMed]
0002-914919.
Gertz
MA
, Falk
RH
, Skinner
M
, Cohen
AS
, Kyle
RA
. Worsening of congestive heart failure in amyloid heart disease treated by calcium channel-blocking agents
. Am J Cardiol
. 1985
Jun
;55
(13 Pt 1
):1645
.
[PubMed]
0002-914920.
Donnelly
JP
, Hanna
M
, Sperry
BW
, Seitz
WH
Jr. Carpal Tunnel Syndrome: A Potential Early, Red-Flag Sign of Amyloidosis
. J Hand Surg Am
. 2019
Oct
;44
(10
):868
–76
.
[PubMed]
0363-502321.
Ward
JE
, Ren
R
, Toraldo
G
, Soohoo
P
, Guan
J
, O’Hara
C
, et al. Doxycycline reduces fibril formation in a transgenic mouse model of AL amyloidosis
. Blood
. 2011
Dec
;118
(25
):6610
–7
.
[PubMed]
0006-497122.
Cardoso
I
, Martins
D
, Ribeiro
T
, Merlini
G
, Saraiva
MJ
. Synergy of combined doxycycline/TUDCA treatment in lowering Transthyretin deposition and associated biomarkers: studies in FAP mouse models
. J Transl Med
. 2010
Jul
;8
(1
):74
.
[PubMed]
1479-587623.
Wechalekar
AD
, Whelan
C
. Encouraging impact of doxycycline on early mortality in cardiac light chain (AL) amyloidosis
. Blood Cancer J
. 2017
Mar
;7
(3
):e546
.
[PubMed]
2044-538524.
Obici
L
, Cortese
A
, Lozza
A
, Lucchetti
J
, Gobbi
M
, Palladini
G
, et al. Doxycycline plus tauroursodeoxycholic acid for transthyretin amyloidosis: a phase II study
. Amyloid
. 2012
Jun
;19
(sup1
Suppl 1
):34
–6
.
[PubMed]
1350-612925.
Witteles
RM
. Doxycycline and Ursodiol for ATTR Amyloidosis: Not Ready for Prime Time
. J Card Fail
. 2019
Mar
;25
(3
):154
–5
.
[PubMed]
1071-916426.
Karlstedt
E
, Jimenez-Zepeda
V
, Howlett
JG
, White
JA
, Fine
NM
. Clinical Experience With the Use of Doxycycline and Ursodeoxycholic Acid for the Treatment of Transthyretin Cardiac Amyloidosis
. J Card Fail
. 2019
Mar
;25
(3
):147
–53
.
[PubMed]
1071-916427.
Castaño
A
, DeLuca
A
, Weinberg
R
, Pozniakoff
T
, Blaner
WS
, Pirmohamed
A
, et al. Serial scanning with technetium pyrophosphate (99mTc-PYP) in advanced ATTR cardiac amyloidosis
. J Nucl Cardiol
. 2016
Dec
;23
(6
):1355
–63
.
[PubMed]
1071-358128.
Adams
D
, Gonzalez-Duarte
A
, O’Riordan
WD
, Yang
CC
, Ueda
M
, Kristen
AV
, et al. Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis
. N Engl J Med
. 2018
Jul
;379
(1
):11
–21
.
[PubMed]
0028-479329.
Koyama
J
, Falk
RH
. Prognostic significance of strain Doppler imaging in light-chain amyloidosis
. JACC Cardiovasc Imaging
. 2010
Apr
;3
(4
):333
–42
.
[PubMed]
1936-878X30.
Dorbala
S
, Ando
Y
, Bokhari
S
, Dispenzieri
A
, Falk
RH
, Ferrari
VA
, et al. ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI Expert Consensus Recommendations for Multimodality Imaging in Cardiac Amyloidosis: Part 1 of 2-Evidence Base and Standardized Methods of Imaging
. J Card Fail
. 2019
Nov
;25
(11
):e1
–39
.
[PubMed]
1071-916431.
Palladini
G
, Barassi
A
, Klersy
C
, Pacciolla
R
, Milani
P
, Sarais
G
, et al. The combination of high-sensitivity cardiac troponin T (hs-cTnT) at presentation and changes in N-terminal natriuretic peptide type B (NT-proBNP) after chemotherapy best predicts survival in AL amyloidosis
. Blood
. 2010
Nov
;116
(18
):3426
–30
.
[PubMed]
0006-497132.
Grogan
M
, Scott
CG
, Kyle
RA
, Zeldenrust
SR
, Gertz
MA
, Lin
G
, et al. Natural History of Wild-Type Transthyretin Cardiac Amyloidosis and Risk Stratification Using a Novel Staging System
. J Am Coll Cardiol
. 2016
Sep
;68
(10
):1014
–20
.
[PubMed]
0735-109733.
Gillmore
JD
, Damy
T
, Fontana
M
, Hutchinson
M
, Lachmann
HJ
, Martinez-Naharro
A
, et al. A new staging system for cardiac transthyretin amyloidosis
. Eur Heart J
. 2018
Aug
;39
(30
):2799
–806
.
[PubMed]
0195-668X34.
Comenzo
RL
, Reece
D
, Palladini
G
, Seldin
D
, Sanchorawala
V
, Landau
H
, et al. Consensus guidelines for the conduct and reporting of clinical trials in systemic light-chain amyloidosis
. Leukemia
. 2012
Nov
;26
(11
):2317
–25
.
[PubMed]
0887-692435.
Swiecicki
PL
, Edwards
BS
, Kushwaha
SS
, Dispenzieri
A
, Park
SJ
, Gertz
MA
. Left ventricular device implantation for advanced cardiac amyloidosis
. J Heart Lung Transplant
. 2013
May
;32
(5
):563
–8
.
[PubMed]
1053-249836.
Maurer
MS
, Elliott
P
, Comenzo
R
, Semigran
M
, Rapezzi
C
. Addressing Common Questions Encountered in the Diagnosis and Management of Cardiac Amyloidosis
. Circulation
. 2017
Apr
;135
(14
):1357
–77
.
[PubMed]
0009-732237.
Sousa
M
, Monohan
G
, Rajagopalan
N
, Grigorian
A
, Guglin
M
. Heart transplantation in cardiac amyloidosis
. Heart Fail Rev
. 2017
May
;22
(3
):317
–27
.
[PubMed]
1382-414738.
Grogan
M
, Gertz
M
, McCurdy
A
, Roeker
L
, Kyle
R
, Kushwaha
S
, et al. Long term outcomes of cardiac transplant for immunoglobulin light chain amyloidosis: The Mayo Clinic experience
. World J Transplant
. 2016
Jun
;6
(2
):380
–8
.
[PubMed]
2220-323039.
Davis
MK
, Lee
PH
, Witteles
RM
. Changing outcomes after heart transplantation in patients with amyloid cardiomyopathy
. J Heart Lung Transplant
. 2015
May
;34
(5
):658
–66
.
[PubMed]
1053-249840.
Mehra
MR
, Canter
CE
, Hannan
MM
, Semigran
MJ
, Uber
PA
, Baran
DA
, et al.; International Society for Heart Lung Transplantation (ISHLT) Infectious Diseases, Pediatric and Heart Failure and Transplantation Councils
. The 2016 International Society for Heart Lung Transplantation listing criteria for heart transplantation: A 10-year update
. J Heart Lung Transplant
. 2016
Jan
;35
(1
):1
–23
.
[PubMed]
1053-249841.
Lacy
MQ
, Dispenzieri
A
, Hayman
SR
, Kumar
S
, Kyle
RA
, Rajkumar
SV
, et al. Autologous stem cell transplant after heart transplant for light chain (Al) amyloid cardiomyopathy
. J Heart Lung Transplant
. 2008
Aug
;27
(8
):823
–9
.
[PubMed]
1053-249842.
Donnelly
JP
, Hanna
M
. Cardiac amyloidosis: an update on diagnosis and treatment
. Cleve Clin J Med
. 2017
Dec
;84
(12
Suppl 3
):12
–26
.
[PubMed]
0891-115043.
Longhi
S
, Quarta
CC
, Milandri
A
, Lorenzini
M
, Gagliardi
C
, Manuzzi
L
, et al. Atrial fibrillation in amyloidotic cardiomyopathy: prevalence, incidence, risk factors and prognostic role
. Amyloid
. 2015
;22
(3
):147
–55
.
[PubMed]
1350-612944.
Falk
RH
, Dubrey
SW
. Amyloid heart disease
. Prog Cardiovasc Dis
. 2010
Jan-Feb
;52
(4
):347
–61
.
[PubMed]
0033-062045.
Rubinow
A
, Skinner
M
, Cohen
AS
. Digoxin sensitivity in amyloid cardiomyopathy
. Circulation
. 1981
Jun
;63
(6
):1285
–8
.
[PubMed]
0009-732246.
Muchtar
E
, Gertz
MA
, Kumar
SK
, Lin
G
, Boilson
B
, Clavell
A
, et al. Digoxin use in systemic light-chain (AL) amyloidosis: contra-indicated or cautious use?
Amyloid
. 2018
Jun
;25
(2
):86
–92
.
[PubMed]
1350-612947.
El-Am
EA
, Dispenzieri
A
, Melduni
RM
, Ammash
NM
, White
RD
, Hodge
DO
, et al. Direct Current Cardioversion of Atrial Arrhythmias in Adults With Cardiac Amyloidosis
. J Am Coll Cardiol
. 2019
Feb
;73
(5
):589
–97
.
[PubMed]
0735-109748.
Barbhaiya
CR
, Kumar
S
, Baldinger
SH
, Michaud
GF
, Stevenson
WG
, Falk
R
, et al. Electrophysiologic assessment of conduction abnormalities and atrial arrhythmias associated with amyloid cardiomyopathy
. Heart Rhythm
. 2016
Feb
;13
(2
):383
–90
.
[PubMed]
1547-527149.
Tan
NY
, Mohsin
Y
, Hodge
DO
, Lacy
MQ
, Packer
DL
, Dispenzieri
A
, et al. Catheter Ablation for Atrial Arrhythmias in Patients With Cardiac Amyloidosis
. J Cardiovasc Electrophysiol
. 2016
Oct
;27
(10
):1167
–73
.
[PubMed]
1045-387350.
Feng
D
, Edwards
WD
, Oh
JK
, Chandrasekaran
K
, Grogan
M
, Martinez
MW
, et al. Intracardiac thrombosis and embolism in patients with cardiac amyloidosis
. Circulation
. 2007
Nov
;116
(21
):2420
–6
.
[PubMed]
0009-732251.
Sucker
C
, Hetzel
GR
, Grabensee
B
, Stockschlaeder
M
, Scharf
RE
. Amyloidosis and bleeding: pathophysiology, diagnosis, and therapy
. Am J Kidney Dis
. 2006
Jun
;47
(6
):947
–55
.
[PubMed]
0272-638652.
Feng
D
, Syed
IS
, Martinez
M
, Oh
JK
, Jaffe
AS
, Grogan
M
, et al. Intracardiac thrombosis and anticoagulation therapy in cardiac amyloidosis
. Circulation
. 2009
May
;119
(18
):2490
–7
.
[PubMed]
0009-732253.
Anderson
KP
. Cardiac Amyloidosis and the Risks of Cardioversion
. J Am Coll Cardiol
. 2019
Feb
;73
(5
):598
–601
.
[PubMed]
0735-109754.
Meier-Ewert
HK
, Sanchorawala
V
, Berk
JL
, Ruberg
FL
. Cardiac amyloidosis: evolving approach to diagnosis and management
. Curr Treat Options Cardiovasc Med
. 2011
Dec
;13
(6
):528
–42
.
[PubMed]
1092-846455.
Dubrey
S
, Pollak
A
, Skinner
M
, Falk
RH
. Atrial thrombi occurring during sinus rhythm in cardiac amyloidosis: evidence for atrial electromechanical dissociation
. Br Heart J
. 1995
Nov
;74
(5
):541
–4
.
[PubMed]
0007-076956.
Grogan
M
, Dispenzieri
A
. Natural history and therapy of AL cardiac amyloidosis
. Heart Fail Rev
. 2015
Mar
;20
(2
):155
–62
.
[PubMed]
1382-414757.
Reisinger
J
, Dubrey
SW
, Lavalley
M
, Skinner
M
, Falk
RH
. Electrophysiologic abnormalities in AL (primary) amyloidosis with cardiac involvement
. J Am Coll Cardiol
. 1997
Oct
;30
(4
):1046
–51
.
[PubMed]
0735-109758.
Sperry
BW
, Vranian
MN
, Hachamovitch
R
, Joshi
H
, McCarthy
M
, Ikram
A
, et al. Are classic predictors of voltage valid in cardiac amyloidosis? A contemporary analysis of electrocardiographic findings
. Int J Cardiol
. 2016
Jul
;214
:477
–81
.
[PubMed]
0167-527359.
Sayed
RH
, Rogers
D
, Khan
F
, Wechalekar
AD
, Lachmann
HJ
, Fontana
M
, et al. A study of implanted cardiac rhythm recorders in advanced cardiac AL amyloidosis
. Eur Heart J
. 2015
May
;36
(18
):1098
–105
.
[PubMed]
0195-668X60.
Ridolfi
RL
, Bulkley
BH
, Hutchins
GM
. The conduction system in cardiac amyloidosis. Clinical and pathologic features of 23 patients
. Am J Med
. 1977
May
;62
(5
):677
–86
.
[PubMed]
0002-934361.
Lin
G
, Dispenzieri
A
, Kyle
R
, Grogan
M
, Brady
PA
. Implantable cardioverter defibrillators in patients with cardiac amyloidosis
. J Cardiovasc Electrophysiol
. 2013
Jul
;24
(7
):793
–8
.
[PubMed]
1045-387362.
Castaño
A
, Drachman
BM
, Judge
D
, Maurer
MS
. Natural history and therapy of TTR-cardiac amyloidosis: emerging disease-modifying therapies from organ transplantation to stabilizer and silencer drugs
. Heart Fail Rev
. 2015
Mar
;20
(2
):163
–78
.
[PubMed]
1382-414763.
Dubrey
SW
, Cha
K
, Anderson
J
, Chamarthi
B
, Reisinger
J
, Skinner
M
, et al. The clinical features of immunoglobulin light-chain (AL) amyloidosis with heart involvement
. QJM
. 1998
Feb
;91
(2
):141
–57
.
[PubMed]
1460-272564.
Patel
KS
, Hawkins
PN
, Whelan
CJ
, Gillmore
JD
. Life-saving implantable cardioverter defibrillator therapy in cardiac AL amyloidosis.
BMJ Case Rep 2014
;2014: 65.
Hamon
D
, Algalarrondo
V
, Gandjbakhch
E
, Extramiana
F
, Marijon
E
, Elbaz
N
, et al. Outcome and incidence of appropriate implantable cardioverter-defibrillator therapy in patients with cardiac amyloidosis
. Int J Cardiol
. 2016
Nov
;222
:562
–8
.
[PubMed]
0167-527366.
Priori
SG
, Blomström-Lundqvist
C
, Mazzanti
A
, Blom
N
, Borggrefe
M
, Camm
J
, et al.; ESC Scientific Document Group
. 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: The Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC). Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC)
. Eur Heart J
. 2015
Nov
;36
(41
):2793
–867
.
[PubMed]
0195-668X67.
Kristen
AV
, Dengler
TJ
, Hegenbart
U
, Schonland
SO
, Goldschmidt
H
, Sack
FU
, et al. Prophylactic implantation of cardioverter-defibrillator in patients with severe cardiac amyloidosis and high risk for sudden cardiac death
. Heart Rhythm
. 2008
Feb
;5
(2
):235
–40
.
[PubMed]
1547-527168.
Varr
BC
, Zarafshar
S
, Coakley
T
, Liedtke
M
, Lafayette
RA
, Arai
S
, et al. Implantable cardioverter-defibrillator placement in patients with cardiac amyloidosis
. Heart Rhythm
. 2014
Jan
;11
(1
):158
–62
.
[PubMed]
1547-527169.
Miani
D
, Rocco
M
, Alberti
E
, Spedicato
L
, Fioretti
PM
. Amyloidosis of epicardial and intramural coronary arteries as an unusual cause of myocardial infarction and refractory angina pectoris
. Ital Heart J
. 2002
Aug
;3
(8
):479
–82
.
[PubMed]
1129-471X70.
Agewall
S
, Beltrame
JF
, Reynolds
HR
, Niessner
A
, Rosano
G
, Caforio
AL
, et al.; WG on Cardiovascular Pharmacotherapy
. ESC working group position paper on myocardial infarction with non-obstructive coronary arteries
. Eur Heart J
. 2017
Jan
;38
(3
):143
–53
.
[PubMed]
1522-964571.
Xiao
Y
, Yin
J
, Wei
J
, Shang
Z
. Incidence and risk of cardiotoxicity associated with bortezomib in the treatment of cancer: a systematic review and meta-analysis
. PLoS One
. 2014
Jan
;9
(1
):e87671
.
[PubMed]
1932-620372.
Bringhen
S
, Milan
A
, D’Agostino
M
, Ferri
C
, Wäsch
R
, Gay
F
, et al. Prevention, monitoring and treatment of cardiovascular adverse events in myeloma patients receiving carfilzomib A consensus paper by the European Myeloma Network and the Italian Society of Arterial Hypertension
. J Intern Med
. 2019
Jul
;286
(1
):63
–74
.
[PubMed]
0954-682073.
Li
W
, Garcia
D
, Cornell
RF
, Gailani
D
, Laubach
J
, Maglio
ME
, et al. Cardiovascular and Thrombotic Complications of Novel Multiple Myeloma Therapies: A Review
. JAMA Oncol
. 2017
Jul
;3
(7
):980
–8
.
[PubMed]
2374-243774.
Palumbo
A
, Rajkumar
SV
, San Miguel
JF
, Larocca
A
, Niesvizky
R
, Morgan
G
, et al. International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation
. J Clin Oncol
. 2014
Feb
;32
(6
):587
–600
.
[PubMed]
0732-183X75.
Pegourie
B
, Karlin
L
, Benboubker
L
, Orsini-Piocelle
F
, Tiab
M
, Auger-Quittet
S
, et al.; IFM Group
. Apixaban for the prevention of thromboembolism in immunomodulatory-treated myeloma patients: Myelaxat, a phase 2 pilot study
. Am J Hematol
. 2019
Jun
;94
(6
):635
–40
.
[PubMed]
0361-860976.
Dispenzieri
A
, Dingli
D
, Kumar
SK
, Rajkumar
SV
, Lacy
MQ
, Hayman
S
, et al. Discordance between serum cardiac biomarker and immunoglobulin-free light-chain response in patients with immunoglobulin light-chain amyloidosis treated with immune modulatory drugs
. Am J Hematol
. 2010
Oct
;85
(10
):757
–9
.
[PubMed]
0361-860977.
Gertz
MA
. Immunoglobulin light chain amyloidosis: 2018 Update on diagnosis, prognosis, and treatment
. Am J Hematol
. 2018
Sep
;93
(9
):1169
–80
.
[PubMed]
0361-860978.
Berk
JL
, Suhr
OB
, Obici
L
, Sekijima
Y
, Zeldenrust
SR
, Yamashita
T
, et al.; Diflunisal Trial Consortium
. Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial
. JAMA
. 2013
Dec
;310
(24
):2658
–67
.
[PubMed]
0098-7484© 2020 S. Karger AG, Basel
2020
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
